250 related articles for article (PubMed ID: 16113314)
1. Merozoite surface protein 1 of Plasmodium vivax induces a protective response against Plasmodium cynomolgi challenge in rhesus monkeys.
Dutta S; Kaushal DC; Ware LA; Puri SK; Kaushal NA; Narula A; Upadhyaya DS; Lanar DE
Infect Immun; 2005 Sep; 73(9):5936-44. PubMed ID: 16113314
[TBL] [Abstract][Full Text] [Related]
2. Biochemical and immunological characterization of E. coli expressed 42 kDa fragment of Plasmodium vivax and P. cynomolgi bastianelli merozoite surface protein-1.
Kaushal DC; Kaushal NA; Narula A; Kumar N; Puri SK; Dutta S; Lanar DE
Indian J Biochem Biophys; 2007 Dec; 44(6):429-36. PubMed ID: 18320841
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of a plasmid DNA vaccine encoding 42kDa fragment of Plasmodium vivax merozoite surface protein-1.
Sheikh IH; Kaushal DC; Chandra D; Kaushal NA
Acta Trop; 2016 Oct; 162():66-74. PubMed ID: 27311385
[TBL] [Abstract][Full Text] [Related]
4. Plasmodium vivax, P. cynomolgi, and P. knowlesi: identification of homologue proteins associated with the surface of merozoites.
Barnwell JW; Galinski MR; DeSimone SG; Perler F; Ingravallo P
Exp Parasitol; 1999 Mar; 91(3):238-49. PubMed ID: 10072326
[TBL] [Abstract][Full Text] [Related]
5. Evidence for strain-specific protective immunity against blood-stage parasites of Plasmodium cynomolgi in toque monkey.
Wijayalath WA; Cheesman S; Rajakaruna J; Handunnetti SM; Carter R; Pathirana PP
Parasite Immunol; 2008; 30(11-12):630-6. PubMed ID: 19067844
[TBL] [Abstract][Full Text] [Related]
6. Comparison of immunogenicities of recombinant Plasmodium vivax merozoite surface protein 1 19- and 42-kiloDalton fragments expressed in Escherichia coli.
Sachdeva S; Ahmad G; Malhotra P; Mukherjee P; Chauhan VS
Infect Immun; 2004 Oct; 72(10):5775-82. PubMed ID: 15385477
[TBL] [Abstract][Full Text] [Related]
7. Immune responses elicited by co-immunization of Plasmodium vivax and P. falciparum MSP-1 using prime-boost immunization strategies.
Mehrizi AA; Zakeri S; Rafati S; Salmanian AH; Djadid ND
Parasite Immunol; 2011 Nov; 33(11):594-608. PubMed ID: 21883290
[TBL] [Abstract][Full Text] [Related]
8. Plasmodium: immunization with carboxyl-terminal regions of MSP-1 protects against homologous but not heterologous blood-stage parasite challenge.
Rotman HL; Daly TM; Long CA
Exp Parasitol; 1999 Jan; 91(1):78-85. PubMed ID: 9920045
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and protective efficacy of three DNA vaccines encoding pre-erythrocytic- and erythrocytic-stage antigens of Plasmodium cynomolgi in rhesus monkeys.
Bhardwaj D; Hora B; Singh N; Puri SK; Lalitha P; Rupa P; Chauhan VS
FEMS Immunol Med Microbiol; 2002 Sep; 34(1):33-43. PubMed ID: 12208604
[TBL] [Abstract][Full Text] [Related]
10. Cloning, overexpression and characterization of soluble 42kDa fragment of merozoite surface protein-1 of Plasmodium vivax.
Sheikh IH; Kaushal DC; Singh V; Kumar N; Chandra D; Kaushal NA
Protein Expr Purif; 2014 Nov; 103():64-74. PubMed ID: 25195175
[TBL] [Abstract][Full Text] [Related]
11. Partial protection against Plasmodium vivax blood-stage infection in Saimiri monkeys by immunization with a recombinant C-terminal fragment of merozoite surface protein 1 in block copolymer adjuvant.
Yang C; Collins WE; Sullivan JS; Kaslow DC; Xiao L; Lal AA
Infect Immun; 1999 Jan; 67(1):342-9. PubMed ID: 9864235
[TBL] [Abstract][Full Text] [Related]
12. Purification, characterization, and immunogenicity of a disulfide cross-linked Plasmodium vivax vaccine candidate antigen, merozoite surface protein 1, expressed in Escherichia coli.
Dutta S; Ware LA; Barbosa A; Ockenhouse CF; Lanar DE
Infect Immun; 2001 Sep; 69(9):5464-70. PubMed ID: 11500418
[TBL] [Abstract][Full Text] [Related]
13. Antigenicity, immunogenicity, and protective efficacy of Plasmodium vivax MSP1 PV200l: a potential malaria vaccine subunit.
Valderrama-Aguirre A; Quintero G; Gómez A; Castellanos A; Pérez Y; Méndez F; Arévalo-Herrera M; Herrera S
Am J Trop Med Hyg; 2005 Nov; 73(5 Suppl):16-24. PubMed ID: 16291762
[TBL] [Abstract][Full Text] [Related]
14. Gamma interferon levels and antibody production induced by two PvMSP-1 recombinant polypeptides are associated with protective immunity against P.vivax in Aotus monkeys.
Barrero CA; Delgado G; Sierra AY; Silva Y; Parra-Lopez C; Patarroyo MA
Vaccine; 2005 Jul; 23(31):4048-53. PubMed ID: 15893858
[TBL] [Abstract][Full Text] [Related]
15. Splenectomised and spleen intact Aotus monkeys' immune response to Plasmodium vivax MSP-1 protein fragments and their high activity binding peptides.
Sierra AY; Barrero CA; Rodriguez R; Silva Y; Moncada C; Vanegas M; Patarroyo MA
Vaccine; 2003 Oct; 21(27-30):4133-44. PubMed ID: 14505893
[TBL] [Abstract][Full Text] [Related]
16. Genetic diversity in the C-terminal 42 kDa region of merozoite surface protein-1 of Plasmodium vivax (PvMSP-1(42)) among Indian isolates.
Thakur A; Alam MT; Sharma YD
Acta Trop; 2008 Oct; 108(1):58-63. PubMed ID: 18823930
[TBL] [Abstract][Full Text] [Related]
17. Lineage-specific positive selection at the merozoite surface protein 1 (msp1) locus of Plasmodium vivax and related simian malaria parasites.
Sawai H; Otani H; Arisue N; Palacpac N; de Oliveira Martins L; Pathirana S; Handunnetti S; Kawai S; Kishino H; Horii T; Tanabe K
BMC Evol Biol; 2010 Feb; 10():52. PubMed ID: 20167126
[TBL] [Abstract][Full Text] [Related]
18. Recent independent evolution of msp1 polymorphism in Plasmodium vivax and related simian malaria parasites.
Tanabe K; Escalante A; Sakihama N; Honda M; Arisue N; Horii T; Culleton R; Hayakawa T; Hashimoto T; Longacre S; Pathirana S; Handunnetti S; Kishino H
Mol Biochem Parasitol; 2007 Nov; 156(1):74-9. PubMed ID: 17706800
[TBL] [Abstract][Full Text] [Related]
19. Direct effect of Plasmodium vivax recombinant vaccine candidates AMA-1 and MSP-119 on the innate immune response.
Bueno LL; Fujiwara RT; Soares IS; Braga EM
Vaccine; 2008 Feb; 26(9):1204-13. PubMed ID: 18242795
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of Plasmodium vivax merozoite surface protein-9 recombinant proteins expressed in E. coli.
Oliveira-Ferreira J; Vargas-Serrato E; Barnwell JW; Moreno A; Galinski MR
Vaccine; 2004 May; 22(15-16):2023-30. PubMed ID: 15121316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
